文献类型：期刊文献

英文题名：The liver-gut axis perspective: Exploring the pathogenesis of fatty liver

作者：Yang, Zonghui[1];Zhang, Jinbao[1,2,3,4];Liu, Xiaona[1];Chen, Honggang[1,3,4];Duan, Haijing[1,2,4];Wang, Qian[5];Zhao, Wenlong[1,2,3,4];Jin, Ling[1,2,3,4]

第一作者：Yang, Zonghui

通信作者：Zhang, JB[1];Zhao, WL[1];Jin, L[1];Wang, Q[2];Jin, L[3]

机构：[1]Gansu Univ Chinese Med, Coll Pharm, Lanzhou, Peoples R China;[2]Northwest Collaborat Innovat Ctr Tradit Chinese Me, Rehabil Ctr, Lanzhou, Peoples R China;[3]Engn Res Ctr Evaluat, Protect & Utilizat Rare Tradit Chinese Med Resourc, Lanzhou, Gansu, Peoples R China;[4]Gansu Pharmaceut Ind Innovat Res Inst, Lanzhou, Peoples R China;[5]Gansu Univ Tradit Chinese Med, Clin Coll Chinese Med, Lanzhou, Peoples R China

第一机构：甘肃中医药大学药学院（西北中藏药协同创新中心办公室）

通信机构：[1]corresponding author), Gansu Univ Chinese Med, Coll Pharm, Lanzhou, Peoples R China;[2]corresponding author), Gansu Univ Tradit Chinese Med, Clin Coll Chinese Med, Lanzhou, Peoples R China;[3]corresponding author), Gansu Univ Chinese Med, 35 Dingxi East Rd, Chengguan Dist, Lanzhou, Peoples R China.|[10735]甘肃中医药大学;[1073501e14fb35863569f]甘肃中医药大学药学院（西北中藏药协同创新中心办公室）;

年份：2025

卷号：1002

外文期刊名：EUROPEAN JOURNAL OF PHARMACOLOGY

收录：;Scopus(收录号：2-s2.0-105007760708);WOS:【SCI-EXPANDED(收录号:WOS:001510130000001)】；

基金：This work was supported by Gansu Provincial University Teachers ' Innovation Fund (No. 2025A-107) and Gansu Provincial Natural Science Foundation (No. 25JRRA931) .

语种：英文

外文关键词：Fatty liver; Alcoholic liver disease; Non-alcoholic fatty liver disease; Liver-gut axis; Therapy

摘要：Fatty liver is one of the most common chronic liver diseases globally, affecting approximately a quarter of the world's population. It poses a significant burden on global health. Its pathogenesis is highly complex. In recent years, increasing attention has been paid to exploring the pathogenesis of fatty liver from the perspective of the liver-gut axis. We first discuss the liver-gut axis in fatty liver, detailing the bidirectional communication between the liver and the intestines. Specifically, the liver releases primary bile acids and numerous bioactive mediators into the biliary tract and systemic circulation, which then interact with the intestine. Conversely, intestinal microorganisms and their metabolites are transported to the liver via the portal vein, thereby influencing liver function. In addition, the interactions between intestinal microbes, the host's immune system, and various soluble factors are described, including their contributions to fatty liver development. Second, we describe the mediators of communication between the intestine and the liver in the pathological state of fatty liver, focusing on three key substances: endotoxins, bile acids, and short-chain fatty acids. Third, we summarize the emerging treatments derived from the liver-gut axis in fatty liver, highlighting frontier findings that may lead to the development of novel therapies. Finally, we offer suggestions for future research directions. We hope that future studies will propose better research strategies for the interaction of the liver-gut axis to promote the development of new treatment strategies and the discovery of precise therapeutic targets for fatty liver.